Bringing you live news and features since 2006 

Cancer Immunotherapy ETF marks one-year anniversary


The Loncar Cancer Immunotherapy ETF (CNCR) has completed its first year.

The first and only exchange-traded fund (ETF) to exclusively hold shares of public companies that are dedicated to immunotherapy research and development, CNCR is based on the Loncar Cancer Immunotherapy Index, developed by biotechnology investor and Loncar Investments CEO Brad Loncar.
“Cancer immunotherapy is an important sector in biotechnology that is transforming how many cancers are treated,” Loncar says. “I am grateful for the opportunity to support companies and researchers that work hard every day to improve the lives of courageous patients who battle cancer disease.”
As of quarter end on 30 September 2016, CNCR had 23,176,170 in assets and there were 900,000 shares outstanding.

Latest News

Raymond James Investment Management plans to launch an ETF product platform in 2025 to support strong client demand in alignment..
Aniket Ullal, Director of ETF Data and Research at CFRA Research, has written a note looking at ETFs with exposure..
Tradeweb reports the following data derived from trading activity on the Tradeweb Markets institutional European- and US-listed ETF platforms...
iShares writes that its assets under management have reached USD4 trillion. The firm says this comes off the back of..

Related Articles

Scott Kefer, VictoryEx Capital Holdings
Bailey McCann writes that active ETFs are capturing investor interest, according to the latest data from Morningstar, which finds that...
Chris Lo, Columbia Threadneedle
In a recent insight on India by Columbia Threadneedle Investments, the firm reports that the country’s economic reforms, which aim...
With an election on the horizon in the United States a group of ETFs is poised to capture investments on...
Robot worker
Qraft Technologies, based in South Korea, specialises in the use of AI in security selection and portfolio construction....
Subscribe to the ETF Express newsletter

Subscribe for access to our weekly newsletter, newsletter archive, updates on the site and exclusive email content.

Marketing by